{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:20:50Z","timestamp":1780932050975,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C11225\/A12402"],"award-info":[{"award-number":["C11225\/A12402"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUKE\/11\/016"],"award-info":[{"award-number":["CRUKE\/11\/016"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["C22436\/A25354"],"award-info":[{"award-number":["C22436\/A25354"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T02:18:49Z","timestamp":1655173129000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Anjali","family":"Zarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-2230","authenticated-orcid":false,"given":"Sarah","family":"Pirrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2690-6583","authenticated-orcid":false,"given":"Clive","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Hodgkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9777-1394","authenticated-orcid":false,"given":"David","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Fife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"MacDonald-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Vasudev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Porfiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2022.06.012_bib0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.012_bib0002","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.012_bib0003","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clgc.2022.06.012_bib0004","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2022.06.012_bib0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2022.06.012_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2022.06.012_bib0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2022.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2022.06.012_bib0009","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.012_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2022.06.012_bib0011","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib Versus Sunitinib in patients with metastatic renal cell carcinoma: pisces study","volume":"32","author":"Escudier","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.clgc.2022.06.012_bib0012","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2022.06.012_bib0013","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9460","key":"10.1016\/j.clgc.2022.06.012_bib0014","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(05)17965-3","article-title":"A proposed charter for clinical trial data monitoring committees: helping them to do their job well","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clgc.2022.06.012_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.012_bib0016","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2022.06.012_bib0017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/0959-8049(95)00664-8","article-title":"Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution","volume":"32","author":"Buccheri","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.clgc.2022.06.012_bib0018","unstructured":"Program CTE. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. US Department of Health and Human Services, NIH, NCI. 2010."},{"issue":"4","key":"10.1016\/j.clgc.2022.06.012_bib0019","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2307\/2533268","article-title":"Incorporating toxicity considerations into the design of two-stage phase II clinical trials","volume":"51","author":"Bryant","year":"1995","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.clgc.2022.06.012_bib0020","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/j.clgc.2019.07.006","article-title":"Validation of the IMDC prognostic model in patients with metastatic renal-cell carcinoma treated with first-line axitinib: a multicenter retrospective study","volume":"17","author":"Konishi","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2022.06.012_bib0021","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euo.2019.06.004","article-title":"Temsirolimus versus Pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase ii trial","volume":"3","author":"Tannir","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.012_bib0022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ijc.33238","article-title":"First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: final results of the FLIPPER trial","volume":"148","author":"Staehler","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2022.06.012_bib0023","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2022.06.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-021-03632-6","article-title":"Comorbidity and frailty assessment in renal cell carcinoma patients","author":"Courcier","year":"2021","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2022.06.012_bib0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40266-019-00644-1","article-title":"Treatment decisions for metastatic clear cell renal cell carcinoma in older patients: the role of tkis and immune checkpoint inhibitors","volume":"36","author":"Esther","year":"2019","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.clgc.2022.06.012_bib0026","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era","volume":"26","author":"van de Haar","year":"2020","journal-title":"Nat Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:42Z","timestamp":1778819322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322001367"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}